In the phase 3 study by Gordon and colleagues, infections were present in 27% of efalizumab treated patients compared to 23 % of those receiving placebo. Among these subjects, there was no increased susceptibility to any specific pathogen determined upon analy sis. In all three phase 3 studies by Gordon et al., Lebwohl et al. and Leonardi et al., no statistically significant increased risk of infection was found in the efali-zumab treated patients compared to those subjects receiving placebo.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.